Interestingly, Dasatinib, a dual tyrosine kinase/SIK2 inhibitor, has been identified as an anti-fibrotic agent in mice with pulmonary fibrosis [10, 11], suggesting that SIK2 inhibition might be an effective anti-fibrosis therapeutic approach. The gene discussed is SIK2; the disease is pulmonary fibrosis.